Cancer Therapeutics Market Size - Global Industry, Share, Analysis, Trends and Forecast 2025 - 2033

Cancer Therapeutics Market Highlights

• The global cancer therapeutics market is expected to reach USD 381.5 billion by 2033, with a CAGR of 7.9% from 2025 to 2033
• The North America cancer therapeutics market was valued at approximately USD 71.7 billion in 2024
• According to Cancer Progress Report, in the United States alone, an estimated 1,958,310 new cases of cancer were diagnosed in 2023 and 609,820 people have died from the disease
• The Asia-Pacific market is projected to grow at a CAGR of over 8.8% from 2025 to 2033
• According to National Institute of Health (NIH), estimated number of incident cases of cancer in India for the year 2022 was found to be 1,461,427 and one in nine people are likely to develop cancer in his/her lifetime
• The hospitals sub-segment as a end-user covers notable share in market
• Development of mRNA cancer vaccines during the COVID-19 pandemic, researchers are fast-tracking personalized cancer vaccines is a popular market trend that fuels the industry demand

Cancer therapeutics refers to the non-surgical and non-radiotherapeutic treatment of cancer patients, which is an important element of medical oncology. These therapies are offered for a wide range of cancer types, including blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. The treatment choices include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. These treatments are typically used in hospitals, specialty clinics, and cancer and radiation therapy facilities.

According to the World Health Organization (WHO), cancer is the world's second biggest cause of mortality, accounting for roughly one in every six fatalities. Furthermore, almost 70% of cancer-related deaths happen in low- and middle-income nations.

Global Cancer Therapeutics Market Dynamics

Market Drivers

• Increasing global cancer incidence boosts demand for novel therapies
• Targeted therapies and immunotherapies enhance treatment efficacy
• Strong investments in oncology research accelerate drug development

Market Restraints

• Expensive drug development and therapies limit patient accessibility
• Strict approval processes delay market entry of new drugs
• Adverse reactions hinder patient adherence and treatment adoption

Market Opportunities

• Innovations in cell therapies and gene editing open new treatment avenues
• AI-driven research accelerates cancer drug development and precision medicine
• Increased investments in healthcare infrastructure drive market growth

Cancer Therapeutics Market Report Coverage

Cancer Therapeutics Market Insights

The rising prevalence of cancer worldwide, fueled by changing lifestyles, is a major driver of market expansion. The World Health Organization (WHO) estimates that 20 million new cancer diagnoses and 9.7 million deaths would be reported in 2022, with 53.5 million people surviving within five years of diagnosis. Approximately one in every five people will get cancer at some point in their lives, with one in every nine men and one in every twelve women dying from it. Furthermore, increased government initiatives to raise cancer awareness around the world are driving market growth.

Ongoing R&D efforts by leading industry players, combined with the increased deployment of Patient Assistance Programs (PAPs) and a boom in strategic acquisitions and collaborations are considerably driving market value. In January 2025, Eli Lilly purchased Scorpion Therapeutics' mutant-selective PI3Kα inhibitor product, STX-478. The drug is currently in Phase I/II clinical trials for breast cancer and other advanced solid tumors.

However, the high cost of drug research and the severe side effects of cancer medicines limit market expansion. Furthermore, volatility in reimbursement rules is projected to stymie market growth. On the other hand, rising demand for individualized medicine and expanding purchasing power in emerging economies create lucrative potential for future expansion.

According to the Press Information Bureau, India has made significant advances in cancer prevention, treatment, and research through policy reforms, enhanced healthcare infrastructure, and financial assistance programs. The Union Budget 2025-26 prioritizes cancer care improvements through programs such as Day Care Cancer Centres and customs tax waivers on life-saving medications. Programs such as NPCDCS, PMJAY, and HMCPF make affordable therapy and early detection possible, while research initiatives like NexCAR19 and the National Cancer Grid continue to develop cancer care. These government measures in India are projected to further fuel the cancer treatments market throughout the forecast period.

Cancer Therapeutics Market Segmentation

The worldwide market for cancer therapeutics is split based on treatment, type, application, end-user, and geography.

Cancer Therapeutics Market By Treatment Type

• Immunotherapy
• Chemotherapy
• Hormonal Therapy
• Targeted Therapy
• Others

According to cancer therapeutics industry analysis, targeted therapy has the biggest market share in 2024 and is likely to maintain its dominance during the forecast period. Its benefits, which include less damage to normal cells, fewer side effects, increased effectiveness, and a higher quality of life, lead to its widespread use. Furthermore, targeted therapy works by blocking certain proteins or genes, preventing cancer cells from growing and spreading, which drives market growth.

Cancer Therapeutics Market By Top Selling Drugs

• Keytruda
• Darzalex
• Perjeta
• Avastin
• Opdivo
• Zytiga
• Velcade
• Herceptin
• Rituxan
• Imbruvica
• Tarceva
• Alimta
• Revlimid
• Xtandi
• Ibrance
• Gleevec
• Temodar
• Others

According to cancer therapeutics industry analysis, revlimid is predicted to hold its position due to its efficacy in treating multiple myeloma and other blood malignancies. Its broad use, combined with positive clinical outcomes, has contributed to its large market share. The medicine improves immune system function and inhibits cancer cell proliferation, making it a popular choice among oncologists. With increased cancer incidence and continued research, Revlimid's market position is expected to stay strong in the next years.

Cancer Therapeutics Market By Application

• Blood Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Breast Cancer
• Cervical Cancer
• Head and Neck Cancer
• Glioblastoma
• Malignant Meningioma
• Mesothelioma
• Melanoma
• Others

According to cancer therapeutics industry analysis, the breast cancer segment is expected to dominate, and it is predicted to remain so throughout the projection period. The increased acceptance of changing lifestyles among women around the world is a major driver of market demand. According to the US National Cancer Institute, breast cancer was the most commonly diagnosed cancer among all estimated new cases that year. Furthermore, the National Breast Cancer Foundation estimates that one in every eight women in the United States will be diagnosed with breast cancer during her lifetime. In 2025, an estimated 316,950 women and 2,800 men will be diagnosed with invasive breast cancer, with an additional 59,080 new instances of non-invasive (in situ) breast cancer.

Cancer Therapeutics Market By End-User

• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

According to cancer therapeutics market forecast, hospitals are the primary end consumers due to their superior healthcare infrastructure and availability of specialist oncology treatments. They offer comprehensive cancer care, which includes chemotherapy, immunotherapy, targeted therapy, and hormone therapy, resulting in better patient results. The presence of qualified medical experts and cutting-edge technology enhances hospitals' involvement in cancer therapy. With the increasing frequency of cancer, hospitals are projected to continue to dominate the market as main treatment facilities.

Cancer Therapeutics Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of LATAM

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Cancer Therapeutics Market Regional Analysis

In terms of regional segments, North America has the highest share of the cancer treatments market and is likely to maintain its dominance during the forecast period. This considerable market presence is fueled by increasing cancer prevalence in major countries and rising adoption of modern cancer treatments. According to the Canadian Cancer Society, over two-fifths of Canadians are forecast to be diagnosed with cancer in their lifetime, with approximately one-fourth expected to perish.

Meanwhile, the Asia-Pacific region's cancer therapeutics business is rapidly expanding, driven by improved healthcare infrastructure and increased availability of novel medicines. For example, in January 2025, CytoMed Therapeutics collaborated with SunAct Cancer Institute to study the efficacy, potency, safety, and tolerability of its allogeneic gamma delta T cells in treating various cancers in India. Rising cancer rates and increased healthcare investments all contribute to the region's market growth.

Cancer Therapeutics Market Players

Some of the top cancer therapeutics companies offered in our report include Novartis AG, AbbVie Inc., Pfizer Inc, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, and Merck & Co., Inc.